$175 Million is the total value of UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's 41 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EOCWU | ELLIOTT OPPORTUNITY II CORP | $20,240,000 | +1.1% | 2,000,000 | 0.0% | 11.57% | -24.7% | |
| CDAK | CODIAK BIOSCIENCES INC | $13,833,000 | -11.9% | 847,108 | 0.0% | 7.90% | -34.4% | |
| IMTX | IMMATICS NV | $9,067,000 | +12.0% | 697,431 | 0.0% | 5.18% | -16.6% | |
| TXN | TEXAS INSTRUMENTS INC | $6,151,000 | -0.0% | 32,000 | 0.0% | 3.52% | -25.5% | |
| SOLY | SOLITON INC | $1,527,000 | -9.5% | 75,000 | 0.0% | 0.87% | -32.5% | |
| PLXP | PLX PHARMA INC | $1,210,000 | +39.9% | 62,673 | 0.0% | 0.69% | +4.1% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $172,000 | +4.9% | 35,714 | 0.0% | 0.10% | -22.2% | |
| TFFP | TFF PHARMACEUTICALS INC | $170,000 | -19.8% | 22,066 | 0.0% | 0.10% | -40.5% | |
| APEN | APOLLO ENDOSURGERY INC | $141,000 | +11.9% | 15,601 | 0.0% | 0.08% | -16.5% | |
| POR | PORTLAND GENERAL ELECTRIC CO | $6,000 | +20.0% | 118 | 0.0% | 0.00% | -25.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEXAS INSTRUMENTS INC | 41 | Q3 2023 | 31.2% |
| PORTLAND GENERAL ELECTRIC CO | 38 | Q3 2023 | 0.0% |
| LEXICON PHARMACEUTICALS INC | 33 | Q3 2023 | 1.7% |
| AEGLEA BIOTHERAPEUTICS INC | 27 | Q2 2023 | 11.0% |
| APOLLO ENDOSURGERY INC | 24 | Q1 2023 | 5.6% |
| PLX PHARMA INC | 23 | Q1 2023 | 1.7% |
| VANGUARD MSCI EMERGING MKTS | 22 | Q2 2019 | 10.3% |
| VANGUARD ENERGY ETF | 22 | Q2 2019 | 8.7% |
| VANGUARD S&P 500 ETF | 21 | Q3 2023 | 11.8% |
| VANGUARD MSCI EAFE ETF | 20 | Q2 2019 | 13.1% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Taysha Gene Therapies, Inc. | September 24, 2021 | 1,156,255 | 3.0% |
| ZIOPHARM ONCOLOGY INC | February 12, 2016 | 9 | 0.0% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-01 |
| 3 | 2024-04-30 |
| 13F-HR | 2024-04-30 |
| 144 | 2024-04-29 |
| SC 13G | 2024-03-05 |
| 13F-HR | 2024-02-28 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-04 |
| 3 | 2023-06-02 |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.